References
- Mokdad AH, Ford ES, Bowman BA, et al. Diabetes trends in the US: 1990–1998. Diabetes Care 2000; 23(9): 1278–83
- American Diabetes Association. Economic consequences of diabetes mellitus in the US in 1997. Diabetes Care 1998; 21(2): 296–309
- DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999, 131(4): 281–303
- Polonsky KS, Sturis J, Bell GI. Non-insulin-dependent diabetes mellitus—a genetically programmed failure of the beta cell to compensate for insulin resistance. Seminars in Medicine of the Beth Israel Hospital, Boston. N Engl J Med 1996; 334(12): 777–83
- Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321(7258): 405–12
- Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am 1997; 26(3): 511–22
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837–53
- Goldberg RB, Einhorn D, Lucas CP, et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998; 21(11): 1897–903
- Horton ES, Clinkingbeard C, Gatlin M, et al. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000; 23(11): 1660–5
- Lebovitz HE. Alpha-glucosidase inhibitors. Endocrinol Metab Clin North Am 1997; 26(3): 539–52
- Johansen K. Efficacy of metformin in the treatment of NIDDM: metaanalysis. Diabetes Care 1999; 22(1): 33–7
- UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352(9131): 854–65
- Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther 2000; 22(10): 1151–68
- Gillies PS, Dunn CJ. Pioglitazone. Drugs 2000; 60(2): 333–43
- Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypo-glycemic effects of thiazolidinediones. Ann Intern Med 2001; 134(1): 61–71
- Khan MA, St Peter JV, Neafus KL, et al. A prospective, randomized comparison of the metabolic effects of pioglitazone vs rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone. (Abstr) Diabetes 2001; 50(Suppl 2): A119
- Thomas JC, Taylor KB. Effects of thiazolidinediones on lipoprotein subclasses in patients who are insulin resistant. (Abstr) Diabetes 2001; 50(Suppl 2): A455
- Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281 (21): 2005–12
- Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24(4): 758–67
- Mensing C, Boucher J, Cypress M, et al. National standards for diabetes self-management education. Diabetes Care 2001; 24(Suppl 1): S126
- American Diabetes Association. Postprandial blood glucose. Diabetes Care 2001; 24(4): 775–8
- Pozzilli P, Di Mario U. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of the adult): definition, characterization, and potential prevention. Diabetes Care 2001; 24(8): 1460–7